CONFIDENCE trial: In persons with chronic kidney disease and type 2 diabetes, combination therapy with finerenone and empagliflozin led to a greater reduction in the urinary albumin-to-creatinine ratio than either drug alone. Full trial results and Research Summary: nej.md/4jEVbbk
ALT The New England Journal of Medicine
Finerenone with Empagliflozin in CKD and Type 2 Diabetes
A Research Summary based on Agarwal R et al. | 10.1056/NEJMoa2410659 | Published on June 5, 2025
Visual representations of the patients in the trial and the treatments they were assigned.
Read the full Research Summary at NEJM.org.
🔬 A look at the top-tier journals in medicine and biomedical science interesting! congratulation on these top tier journals🚀🦾🚀🤩
•The Lancet IF: 98.4
•NEJM IF: 96.2
•The BMJ IF: 93.6
•Nature Medicine IF: 50.0
•JAMA IF: 50.0
•Nature IF: 48.5
From @ESOTtransplant#esotcongress 2025 2 amazing days working with colleagues on the @TheLancet commission. Paving the future of organ transplantation in the next 15 years !!!
Great thing about having the Lancet commission meeting ahead of #ESOT2025 is that you can see an empty congress space quiet before the storm ! looking forward to meeting with colleagues and friends and share science !! @gabriel_oniscu
📢 New publication in Xenotransplantation Journal by our group @ParisTxGroup@AlexandreLoupy !
Among the 2,900 Xeno papers we assessed, 706 focused on solid organ & islet transplants from animals to humans 🐷➡️🧍
lnkd.in/eVKHzNVn
Here’s a summary of what we found 👇
Beyond standard of care monitoring for patients who are post-transplant, urinary chemokine CXCL9 demonstrated limited clinical utility, while CXCL10 provided no additional value. kidney.pub/JASN0742#ASNJASN
Direct from Choose Europe 🇪🇺for Science: A Bold Step from Paris 🇫🇷 !
Transplant researchers: if you’re ready to innovate, 🇫🇷 might be your next destination🛬.
@ParisTxGroup is ready 🚀🤖🦾#PITOR#FranceForScience DM me if interested
Proud of my team @ParisTxGroup and the amazing work done for @ESOTtransplant abstract submission! We are proud of the research submitted in kidney - Heart - Lung - Liver and Xeno ! addressing key challenges and encompassing large trials and cutting edge technologies. @gabriel_oniscu@Olivier_Thaunat
Interested in our team’s @NEJM publication on microvascular inflammation in kidney allografts and its clinical outcomes? Check out the coverage in @pathologistmag, highlighting the key findings and the study’s impact.
thepathologist.com/subspecia…
We recently announced a collection of 40 peer-reviewed papers in @NaturePortfolio marking a significant progress in our understanding of the human body and providing a foundation from which the first version of atlas will be assembled.
nature.com/collections/jccbb…
I had the privilege of being invited to give a lecture @karolinskainst 🇸🇪 Truly honored and inspired to stand so close to the building where the The Nobel Prize are being awarded this week.
A special shoutout to @Gabriel Oniscu @ESOTtransplant for his exceptional leadership.
Which one is the best congress outfit ?
Thank you to the organizers and colleagues from Korea 🇰🇷for an amazing venue and organization as well as high level content.